- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
In the studies by Neely et al., Walsh et al. and Sáez-Llorens et al., the following kinetic parameters were found:
t½ (hours)
12-17 yrs: 11.2±1.7
2-11 yrs: 8.2±2.4
3-23 months: 8.8±2.1
Cl (ml/min)
12-17 yrs 12.6±5.5
2-11 yrs 6.4±2.6
3-23 months 3.2±0.4
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Available formulations
No information is present at this moment.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Dosages
| Candidiasis, aspergillosis, empirical treatment of suspected fungal infections in fever and neutropenia |
|---|
|
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Diarrhoea, dyspnoea, respiratory distress. As in adults, similar histamine-mediated symptoms have been reported.
Children: Very common (> 10%): fever. Common (1–10%): pain at the infusion site, shivers. Headaches. Transient redness of the face and neck, hypotension. Tachycardia. Skin rash, itchiness. Increases in liver enzyme values (ASAT, ALAT). Elevated eosinophil count. Lowered potassium value, hypomagnesemia, lowered and elevated phosphorus value, elevated glucose value/blood sugar level. Also noted: swelling at the infusion site, peripheral oedema, hypocalcaemia, impaired liver function. Nephrotoxicity.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Only prescribe after consulting an infectiologist/microbiologist. The dosage must be adjusted in adults with moderately impaired liver function. No studies have been carried out in children with impaired hepatic function; caution is therefore needed in severe liver function disorders.
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
| Antibiotics | ||
|---|---|---|
| J02AA01 | ||
| Triazole and tetrazole derivatives | ||
|---|---|---|
| J02AC01 | ||
| J02AC02 | ||
| J02AC03 | ||
| Other antimycotics for systemic use | ||
|---|---|---|
| J02AX06 | ||
| J02AX01 | ||
| J02AX05 | ||
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
References
- Zaoutis T, et al, Safety Experience With Caspofungin in Pediatric Patients., Pediatr Infect Dis J., 2009, [Epub ahead of print]
- Walsh TJ, et al, Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents., Antimicrob Agents Chemother., 2005, 49(11), 4536-45
- Fisher BT, et al, Caspofungin for the treatment of pediatric fungal infections., Pediatr Infect Dis J., 2008, 27, 1099-102
- Lehrnbecher T, et al, Experiences with the use of caspofungin in paediatric patients., Mycoses., 2008, 51, 58-64
- Koo A, et al, Efficacy and safety of caspofungin for the empiric management of fever in neutropenic children., Pediatr Infect Dis J., 2007, 26, 854-6
- Merlin E, et al, Efficacy and safety of caspofungin therapy in children with invasive fungal infections, Pediatr Infect Dis J., 2006, 25, 1186-8
- Neely M, et al, Pharmacokinetics and safety of caspofungin in older infants and toddlers., Antimicrob Agents Chemother., 2009, 53, 1450-6
- Sáez-Llorens X, et al, Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age., Antimicrob Agents Chemother., 2009, 53, 869-75
- Zaoutis TE, et al, A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients., Pediatrics, 2009, 123, 877-84
- Jeon GW et al. , Successful caspofungin treatment of persistent candidemia in extreme prematurity at 23 and 24 weeks gestation, J Formos Med Assoc, 2014 , Mar;113(3), 191-4
- Maertens JA et al. , A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia, Pediatr Infect Dis J, 2010, May;29(5), 415-20
- Mohamed WA et al, A randomized, double-blind, prospective study of caspofungin vs. amphotericin B for the treatment of invasive candidiasis in newborn infants., J Trop Pediatr. , 2012, Feb;58(1), 25-30
- Natarajan G et al., Experience with caspofungin in the treatment of persistent fungemia in neonates. , J Perinatol, 2005, Dec;25(12), 770-7
- Odio CM et al, Caspofungin therapy of neonates with invasive candidiasis, Pediatr Infect Dis J, 2004, Dec;23(12), 1093-7
A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.
Changes
Changes
